Filgrastim support during combination chemotherapy using cisplatin, doxorubicin, and cyclophosphamide to treat advanced or recurrent endometrial cancer: A clinical study and literature review

In a private practice setting, 16 patients with advanced or recurrent endometrial carcinoma received cisplatinum 50 mg/m2, doxorubicin 50 mg/m2, and cyclophosphamide 750 mg/m2 every three weeks. Growth factor support using filgrastim was initiated on the first cycle of therapy and each subsequent cycle. Sixteen patients were entered into the study with 13 being evaluable. No patient had previously received chemotherapy. The overall response rate was 54% with two complete responses (15%) and five partial responses (38%). Stable disease was seen in 46% of patients. Progression-free survival was observed to be a median of 8.5 months for a complete response, a median of 8.5 months for a partial response and a median of 7 months for stable disease. Fifteen percent of the patients and 3% of all chemotherapy cycles had febrile neutropenic events. There were no deaths due to myelotoxicity. Only one patient required a dose reduction due to neutropenia. Four of the 13 patients required dose reductions due to previous nadir thrombocytopenia. Grade 4 granulocytopenia occurred in 28% of treatment cycles and grade 3 granulocytopenia occurred in 12% of treatment cycles. The use of filgrastim (G-CSF) allowed patients to stay on therapy for an average of seven treatments. Neutropenia was not the dose-limiting toxicity from this dose-intense regimen.

Cisplatinum; Doxorubicin; Cyclophosphamide; Filgrastim; Endometrial cancer

[1] Moore T.D., Phillips P.H., Nerenstone S.R., Cheson B.C.: "Systemic treatment of advanced and recurrent endometrial caicinoma: current status and future directions". J. Clin. Oneal., 1991, 9, 1071.

[2] T higpen J.T., Blessing J.A., DiSaia P.J., Yordan E., Carson L.F., Evers C.: "A randomized compaiison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study". J. Clin. Oneal., 1994, 12, 1408.

[3] Muss H.B.: "Chemotherapy of metastatic endometrial cancer". Sem. Oncol., 1994, 21 (1), 107.

[4] Burke T.W., Gershenson D.M., Morris M. et al.: "Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma" Gynecol. Oneal., 1994, 55, 47.

[5] Smith M.R., Peters W.A., Drescher C.W.: "Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma". Am. J. Obstet. Gynecol., 1994, 170 (6), 1677.

[6] Dunton C.J., Pfeifer S.M., Braitmen L.E. et al.: "Treatment of advanced and recurrent endometrial cancer with cisplatin,d oxorubicin, and cyclophosphamide". Gynecol. Oneal., 1991, 41,113.

[7] Hancock K.C., Freedman R.S., Edwards C.L. et al.: "Use of cisplatin, doxorubicin and cyclophosphamide to treat advanced and recurrent adenocarcinoma of the endometrium". Cancer Treat Rep., 1986, 70 (6), 789.

[8] Burke T.W., Stringer C.A., Morris M. et al.: "Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin and cyclophosphamide". Gynecol. Oncol., 1991, 40, 264.

[9] Stringer C.A., Gershenson D.M., Burke T.W. et al.: "Adjuvant chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (PAC) for early-stage high-risk endometrial cancer: a preliminary analysis". Gynecol. Oneal., 1990, 38, 305.

[10] Horton J., Begg C.B., Arseneault J. et al.: "Comparison of adnamycin with cyclophosphamide in patients with advanced endometrial cancer". Cancer Treat. Rep., 1978, 62 (1).

[11] Seski J.C., Edwards C.L., Gershenson D.M. et al.: "Doxorubicm and cyclophosphamide chemotherapy for disseminated endometrial cancer". Obstet. Gynecol., 1981, 58, 88.

[12] Thigpen T., Blessing J., DiSaia P. et al.: "A randomized companson of adriamycin with or without cyclophosphamide in the treatment of advanced or recurrent endometrial carcinoma". Proceedings of A SCO,1 985, 4, 115.

[13] Thigpen T., Blessing J., Homesley H. et al.: "Phase III trial of doxorubicin 土cisplatin in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group (GOG) study". Proceedings of A SCO,1 993,12, 261.

[14] Piver M.S., Fanning J., Baker T.R.: "Phase II trial of cisplatin, adriamycin and etoposide for metastatic endometrial adenocarcinoma". Am. J. Clin. Oneal. (CCT), 1991, 14 (3), 200.

[15] Fung Kee Fung M., Krepart G.V., Lotocki R.J. et al.:'Treatment of recurrent and metastatic adenocarcinoma of the endometrium with cisplatin, doxorubicin, cyclophosphamide, and medroxyprogesterone acetate". Obstet. Gynecol., 1991, 78 (6), 1033.

[16] Lovecchio J.L.,A verette H.E.,L ichtinger M. et al.:'Treatment of advanced or recurrent endometrial adenocarcinoma with cyclophosphamide, doxorubicin, cisplatinum, and megestrol acetate". Obstet. Gynecol., 1984, 63 (4), 557.

[17] Deppe G., Lui T.L.: "T noma with cisplatin, cyclophosphamide and doxorubicin". Acta Obstet. Gynecol. Scand., 1985, 64, 83

[18] Turbow M.M., Ballon S.C., Sikic B.I. et al.: "Cisplatin, doxorubicin and cyclophosphamide chemotherapy for advanced endometrial carcinoma". Cancer Treat. Rep., 1985, 69 (5), 465.

[19] Edmonson J.H., Krook J.E., Hilton J.F. et al.: "Randomized phase II studies of cisplatin and a combination of cyclophosphamidedoxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma". Gynecol. Oneal., 1987, 28, 20.

[20] Hoffman M.S., Roberts W.S., Cavanagh D. et al.: "Treatment of recurrent and metastatic endometrial cancer with cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate". Gynecol Oneal., 1989, 35, 75.

[21] Koretz M.M., Ballon S., Friedman M.A. et al.: "Platinum, adnamycin, and cyclophosphamide (PAC) chemotherapy in advanced endometrial carcinoma". Proceedings CJ{A m. Assoc. Cancer Res. and ASCO, 1980, 21, 195.